Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis
Guillaume Manson, Aurélien Marabelle, Roch Houot

To cite this version:

HAL Id: hal-01699247
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01699247
Submitted on 28 Feb 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Hair Repigmentation With Anti–PD-1 and Anti–PD-L1 Immunotherapy: A Novel Hypothesis

To the Editor

The article by Rivera et al1 is the first report of a previously undescribed side effect of checkpoint inhibitors: hair repigmentation (HR). In this significant case series of 14 patients, all patients received an anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibody for the treatment of a lung cancer.

We report an additional case illustrating that HR follow-ing PD-1 blockade is not limited to patients with lung cancer. A man in his 70s was diagnosed with Hodgkin lymphoma. Two years after treatment with chemotheraphy, he experienced a relapse and was also diagnosed with metastatic colorectal cancer (CRC-MSI). Both cancers were treated in parallel but progressed within 3 years to involve the liver, lungs, spleen, and lymph nodes. Given the high sensitivity of Hodgkin lymphomas and CRC-MSI to anti-PD-1 antibodies, it was decided to treat the patient with nivolumab (3 mg/kg every 2 weeks).2 The patient experienced a mixed response, with tumor regression at most tumor sites except for a liver metastasis, which was treated with local radiotherapy. The patient remained on nivolumab treatment for a year with acceptable toxic effects (grade 2 fatigue, grade 3 hepatitis, grade 2 hypothyroidism). One month after nivolumab treatment initiation, the patient reported HR of his whole body although he had harbored white hair for the last 25 years.

Hair and skin pigmentation is linked to immunity.3 As mentioned by Rivera et al,1 other drugs can induce HR. Interestingly, most of them have immunomodulatory properties. It is also striking to notice that 14 of the 15 reported cases (including ours) are men. Although some biases may partly explain this sex imbalance (increased incidence of lung cancer in men, underdiagnosis of HR in women owing to hair dye), we make the hypothesis that these observations might highlight a patho-physiological substrate. Indeed, many immune genes are X-linked, some of which are involved in pigmentation disorders (e.g., IKBKG, POLA).4 One of them, FOXP3, the critical driver of regulatory T cells (T-regs), is of peculiar interest because of increasing evidence regarding the role of T-regs in hair biology.5 Thus, immune modulation induced by PD-1/PD-L1 antibody in patients with an X-linked gene polymorphism (e.g., affecting T-regs) may explain both HR and the increased anti-tumor efficacy observed in almost all of these patients. Further studies are warranted to assess this hypothesis.

Guillaume Manson
Aurélien Marabelle, MD, PhD
Roch Houot, MD, PhD

Author Affiliations: Department of Hematology, CHU Rennes, Rennes, France (Manson, Houot); Gustave Roussy, Université Paris-Saclay, Département d’Innovation Therapeutique et d’Essais Précoces, Villejuif, F-94805, France (Marabelle); INSERM U1015, Gustave Roussy, Villejuif, France (Marabelle); INSERM, U1236, Rennes, France (Houot).

Corresponding Author: Roch Houot, MD, PhD, Department of Hematology, CHU Rennes, 2 rue Henri Le Guilloux, 35033 Rennes Cedex 9, France (roch.houot@chu-rennes.fr).

Additional Contributions: We are indebted to Caroline Robert, MD, PhD, Stéphane Champiat, MD, Jean-Pierre Armand, MD, and Jean-Marie Michot, MD, for sharing their expertise on this case. They received no compensation for their contributions.


Conflict of Interest Disclosure: None reported.